Cymab develops multi-specific accumulating antibodies, capturing endogenous cytokines and accumulating them in the tumor or microenvironment. Incorporating effectors ensures effective monotherapy-intended antibody treatments. Cymab started from Hemab Therapeutics and shares the same founder group, but holds it's own IP. Cymab is incubated jointly at the BioInnovation Institute in Copenhagen, Denmark and Hong Kong Shenzhen Innovation and Technology Park and has legal entities both places.